Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017899 | 0.93 | CA1 (0.38) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL6913491 | 0.82 | CA1 (0.50) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL7064883 | 0.82 | CA1 (0.50) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL919145 | 0.82 | CA1 (0.50) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL2690167 | 0.80 | KMT2A (0.52) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL20337323 | 0.80 | KMT2A (0.52) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL10732541 | 0.79 | CA1 (0.43) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL10734273 | 0.78 | CA1 (0.46) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL11476680 | 0.78 | CA1 (0.46) | CA1CA2CA4KMT2ACYP2D6 | |
| SCHEMBL7632295 | 0.77 | KMT2A (0.48) | CA1CA2CA4KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101950599-B | Conductive carbon slurry for membrane switch and preparation method thereof | IRICO GROUP CORP | 2012-01-04 | — | — | CN | claimed |
| CN-101950599-A | Conductive carbon slurry for membrane switch and preparation method thereof | IRICO GROUP CORP | 2011-01-19 | — | — | CN | claimed |
| CN-101950599-B | Conductive carbon slurry for membrane switch and preparation method thereof | IRICO GROUP CORP | 2012-01-04 | — | — | CN | disclosed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| CN-101950599-A | Conductive carbon slurry for membrane switch and preparation method thereof | IRICO GROUP CORP | 2011-01-19 | — | — | CN | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | CA1 790/4885CA2 1529/4885CA4 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.